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tools which may be applied at the point-of-care. TB control
programmes of disease-endemic countries still depend on
sputum smear microscopy which detects only ~50% of
culture positive pulmonary TB cases. Diagnosis of smear-
negative TB in paediatric and HIV populations, and of
extrapulmonary TB present a major challenge. The global
rise of MDR and XDRTB has added to the burden of TB
control programmes in developing countries which lack
laboratory capacity for drug susceptibility testing. Recent
years have seen rapid progress in the development of
new TB diagnostics. The task remains for these tools to
be made accessible to resource-constrained, tuberculosis-
endemic settings where they are most needed.
Light emitting diode (LED) microscopes have been shown to
be more sensitive than Ziehl-Neelsen (ZN) microscopy, with
operational and cost beneﬁts over conventional ﬂuorescent
microscopy and ZN microscopy.
The Xpert® MTB/RIF test (Cepheid, USA), an automated real-
time PCR assay which simultaneously detects Rifampicin
resistance, can be easily performed with little staff training.
It has been recently shown to have high diagnostic accuracy
in smear negative samples and HIV patients in close to point-
of- care settings. The GenoType® MDTBR (Hain LifeScience
GmbH, Germany), a molecular line probe assay based
on reverse hybridization technology, has demonstrated
accuracy for the rapid detection of MDRTB in smear positive
sputum specimens.
Liquid media-based methods for culture and drug
sensitivity testing are faster and more sensitive than
solid media, but require expensive and sophisticated
laboratory infrastructure. The Microscopically Observed
Drug Susceptibility (MODS) assay and thin layer agar (TLA)
assays are inexpensive and rapid tests which have shown
a high degree of accuracy for detection of rifampicin
and isoniazid resistance and have been proposed as an
interim solution in resource-limited settings until capacity
for genotypic or automated liquid culture drug susceptibility
testing is developed.
The interferon gamma release assays (IGRAs) have
demonstrated improved speciﬁcity and sensitivity over the
century old tuberculin skin test (TST) for detection of
latent TB infection. The IGRAs however do not distinguish
between latent and active TB and have a limited role in
diagnosing active TB in endemic settings. There is ongoing
research on the use of these tests on non-blood samples
from compartments of disease (eg bronchoalveolar lavage
ﬂuid) for diagnosis of active TB.
Urine is a convenient clinical specimen, and urinary
mycobacterial lipoarabinomannan (LAM) and trans-renal my-
cobacterial DNA appear promising as diagnostic tools in HIV-
infected individuals with advanced immunosuppression.
It is anticipated that the widespread implementation of
more accurate and rapid diagnostic tools will result in
increased TB case detection. This in turn must lead to
prompt and appropriate treatment of the TB case until
cure.
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Aims: The ﬁrst XDRTB emerged in 2005. Now it is
presented in at least 58 countries. Estimated fatality rate is
approximately 50%. China is one of the world’s 22 countries
with the highest burden of tuberculosis. China is also one of
the world’s 27 countries with the highest burden of MDR-TB/
XDR-TB. However, there is little information on the clinical
characteristics, management and treatment outcomes for
XDRTB patients in China. We try to address this issue by
collecting different reports from China so as to obtain a
whole picture about the features of XDRTB in China.
Methods: All pulmonary TB patients being reported were
diagnosed by sputum culture and their HIV status was
negative. XDR was conformed by DST which was done
on all culture-positive isolates by BACTEC 960 system.
Individualized treatment regimen was tailored by doctors
for these patients on the basis of DST results and history of
drugs taken by the patients. The recommended regimen
by WHO is the combination of at least four drugs to
which the Mycobacterium tuberculosis isolate is likely to
be susceptible. Drugs are chosen with a stepwise selection
process through ﬁve groups on the basis of efﬁcacy,
safety and cost. The clinical characteristics and treatment
outcome of XDRTB patients were compared with non-MDR
retreated patients and non-XDR MDR-TB patients.
Results: XDR PTB patients complained much more clinical
symptoms mainly including cough with sputum, weight loss,
sweating and short of breath as compared to retreated
non-MDR PTB patients. The extent of disease in XDRTB
and non-XDR MDR-TB was both large. At least 3 lung ﬁelds
were involved in 90.5% of XDR-TB patients and in 80.7%
of non-XDR MDR-TB (P= 0.008). 40.5% of XDR-TB patients
were complicated by diabetes, other chronic lung diseases,
liver disease, signiﬁcantly higher as compared with non-XDR
MDR-TB patients (P= 0.002). Micronodules, consolidations,
cavities were the most frequent CT abnormalities and
were seen in all XDR-TB patients (100%). Bronchiectasis,
tree-in-bud appearance, emphysema, pleural effusion,
lymphadenopathy, bronchopleural ﬁstula, empyema and
lobular consolidations were also found. Compared with non-
XDR MDR-TB, XDR-TB showed a signiﬁcantly larger extent of
cavities and consolidation (P< 0.05). With respect to other
CT features, there were no signiﬁcant differences between
them. In general, XDR-TB tends to have more extensive
consolidation and cavities. The resistance rates to other
drugs except for isoniazid and rifampicin were signiﬁcantly
higher in patients with XDR-TB. Average number of drugs to
which resistance was shown in XDR was 7, in non-XDR MDR
was 5.Treatment failure was more common in patients with
XDR-TB. Cure and treatment completion rate in XDR-TB was
only 14.89%, obviously lower than that in non-XDR MDR-TB,
whereas the mortality and treatment default did not differ
signiﬁcantly.
Conclusions: Tuberculosis treatment becomes challenging
following the emergence of MDR/XDRTB. XDR-TB has
signiﬁcantly worse short- and long-term outcomes because
of high resistant rate, extensive lung injury, lack of
potent bactericidal drugs, lengthy treatment duration and
toxicities of second-line medications.
